Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study

Overview

Journal Adv Ther

Date 2024 Mar 5

PMID 38443649

Authors

Daniel J Simmons

Stephen J Valerio

Darren S Thomas

Marcus J Healey

Zhuoxin Jiang

Jesica M Levingston Mac Leod

Yian Lin

Janvi Sah

Affiliations

Soon will be listed here.

Abstract

Introduction: Systemic therapies have been associated with clinically significant events (CSEs) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the incidence of CSEs (bleeding, clotting, encephalopathy, and portal hypertension), and their impact on healthcare resource utilization (HCRU) and costs, in patients with uHCC treated with first-line (1L) atezolizumab plus bevacizumab (A + B), lenvatinib (LEN), or sorafenib (SOR) in the USA.

Methods: A retrospective cohort study was performed using medical/pharmacy claims from Optum Clinformatics Data Mart. Patients diagnosed with HCC who initiated 1L A + B between June 01, 2020 and December 31, 2020 or LEN/SOR between January 01, 2016 and May 31, 2020 were included. Outcomes included incidence rates of CSEs, HCRU, and costs. Subgroup analysis was performed in patients with no CSEs or ≥ 1 CSE.

Results: In total, 1379 patients were selected (A + B, n = 271; LEN, n = 217; SOR, n = 891). Clotting (incidence rate per 100 patient-years [PY] 94.9) and bleeding (88.1 per 100 PY) were the most common CSEs in the A + B cohort. The most common CSEs in the LEN cohort were clotting (78.6 per 100 PY) and encephalopathy (66.3 per 100 PY). Encephalopathy (73.0 per 100 PY) and portal hypertension (72.3 per 100 PY) were the most common CSEs in the SOR cohort. Mean total all-cause healthcare costs per patient per month (PPPM) were $32,742, $35,623, and $29,173 in the A + B, LEN, and SOR cohorts, respectively. Mean total all-cause healthcare costs PPPM were higher in patients who had ≥ 1 CSE versus those who did not (A + B $34,304 versus $30,889; LEN $39,591 versus $30,621; SOR $31,022 versus $27,003).

Conclusion: Despite improved efficacy of 1L systemic therapies, CSEs remain a concern for patients with uHCC, as well as an economic burden to the healthcare system. Newer treatments that reduce the risk of CSEs, while improving long-term survival in patients with uHCC, are warranted.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

Park J, Chen M, Colombo M, Roberts L, Schwartz M, Chen P . Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015; 35(9):2155-66. PMC: 4691343. DOI: 10.1111/liv.12818. View

Petrick J, Kelly S, Altekruse S, McGlynn K, Rosenberg P . Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol. 2016; 34(15):1787-94. PMC: 4966339. DOI: 10.1200/JCO.2015.64.7412. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Fulgenzi C, Scheiner B, Korolewicz J, Stikas C, Gennari A, Vincenzi B . Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials. JHEP Rep. 2023; 5(5):100702. PMC: 10070142. DOI: 10.1016/j.jhepr.2023.100702. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

10.

Chen B, Zhang L, Cheng J, Wu T, Lei J, Yang X . Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study. Drug Des Devel Ther. 2023; 16:4429-4437. PMC: 9805705. DOI: 10.2147/DDDT.S386829. View

11.

Patel N, Maher J, Lie X, Gwaltney C, Barzi A, Karwal M . Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Qual Life Res. 2021; 31(2):473-485. PMC: 8847294. DOI: 10.1007/s11136-021-02903-4. View

12.

Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F . Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol. 2020; 7(3):HEP27. PMC: 7399607. DOI: 10.2217/hep-2020-0024. View

13.

Galle P, Finn R, Qin S, Ikeda M, Zhu A, Kim T . Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(7):991-1001. DOI: 10.1016/S1470-2045(21)00151-0. View

14.

Lal L, Aly A, Le L, Peckous S, Seal B, Teitelbaum A . Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. Cancer Rep (Hoboken). 2021; 5(5):e1504. PMC: 9124510. DOI: 10.1002/cnr2.1504. View

15.

Gandhi S, Khubchandani S, Iyer R . Quality of life and hepatocellular carcinoma. J Gastrointest Oncol. 2014; 5(4):296-317. PMC: 4110497. DOI: 10.3978/j.issn.2078-6891.2014.046. View

16.

Bonafede M, Korytowsky B, Singh P, Cai Q, Cappell K, Jariwala-Parikh K . Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy. J Gastrointest Cancer. 2019; 51(1):217-226. PMC: 7000498. DOI: 10.1007/s12029-019-00230-z. View

17.

Brunocilla P, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A . Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2012; 30(1):345. DOI: 10.1007/s12032-012-0345-2. View

18.

George S, Bell E, Zheng Y, Kim R, White J, Devgan G . The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. Oncologist. 2021; 26(7):e1205-e1215. PMC: 8265346. DOI: 10.1002/onco.13812. View

19.

Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi F, Rovesti G . Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019; 71(6):1175-1183. DOI: 10.1016/j.jhep.2019.08.015. View

20.

Zheng J, Shao M, Yang W, Ren J, Chen X, Yang H . Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis. Int Immunopharmacol. 2022; 112:109244. DOI: 10.1016/j.intimp.2022.109244. View